Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Pharmaceuticals
Tesaro, MD Anderson target small molecules
by Ann M. Thayer
April 4, 2016
| A version of this story appeared in
Volume 94, Issue 14
Biopharmaceutical developer Tesaro and the Institute for Applied Cancer Science (IACS) at the University of Texas MD Anderson Cancer Center will work together to discover and develop drug candidates against immuno-oncology targets. The collaboration is the first for IACS focused on small molecules. IACS will conduct drug discovery research and identify clinical candidates. Tesaro will fund R&D in return for exclusive rights to develop and commercialize any candidates that emerge.
You might also like...
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter